
Applications Open for BioVentures’ CADET Program
Develop commercialization skills through BioVentures’ year-long CADET program. Applications close Aug. 7.
Linking research minds with global markets
BioVentures, as the technology transfer office of the University of Arkansas for Medical Sciences (UAMS), is responsible for managing the intellectual property generated at the institution. Our team, made up of experts in licensing, business development, healthcare sciences, and legal matters, assists inventors and startups in commercializing their technology, thereby contributing to regional economic and social development.
Submit your invention disclosure here and initiate the journey towards commercialization
Learn how to obtain a patent, policies and procedures, and other important details for inventors.
Browse through our intellectual property portfolio and discover the available technology.
Identification, protection, and management of intellectual property (IP) generated from research activities. This includes patent filing and maintenance, copyright registration, and trademark protection.
Development of licensing strategies, negotiation of licensing agreements, and oversight of existing agreements to ensure compliance and manage royalties.
Assistance in the development of commercialization strategies for new technologies, including market analysis and business model development.
Providing support for new business creation, including entrepreneurial guidance, access to incubator space, and connecting to potential investors.
Assistance in identifying and applying for grants and other funding sources to support the development and commercialization of technologies.
Building and managing relationships with industry partners to facilitate research collaborations, co-development projects, and technology licensing.
Ensuring that technology development and commercialization activities comply with relevant laws, regulations, and institutional policies.
Programs for UAMS faculty, trainees, and staff on the IP process, commercialization options, and entrepreneurship.

Develop commercialization skills through BioVentures’ year-long CADET program. Applications close Aug. 7.
BioVentures has released a new podcast episode featuring Dr. Marie Burdine, a member of the most recent AR Health Ventures Accelerator cohort. In the episode, she discusses her team’s research on a drug designed to reduce delayed graft function (DGF),

Newly issued patent enables patient-specific coronary CTA imaging by predicting cardiac motion to improve image quality and accuracy.